NPPA and congestive heart failure: The strategy of enhancing endogenous NPs and their protective roles in CHF is achieved with the drug sacubitril/valsartan, which augments circulating ANP and BNP by inhibiting of neprilysin that degrades NPs (McMurray et al., 2014).